ClinicalTrials.gg
CompletedNCT01465958KIDSUpdated Mar 13, 2015Results posted

Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency

A Phase 4 interventional study of GAMUNEX-C and GAMUNEX-C in Primary Immunodeficiency, sponsored by Grifols Therapeutics LLC. Completed at 4 sites in United States. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2015-03-13.

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
2 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.

Enrollment
25th of 26
12 · median 45
Started
2011
with 6 others
Phase 4
3 of 27
none open now
Registered
15th of 27
by date
Lead sponsor
3 of 27
Grifols Therapeutics LLC

Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 25th largest by enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2011, is one of 3 in phase 4, and was the 15th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:

All 2 open studies →

About Immunoglobulins, Intravenous

Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, or all of them as a file.
02

Study summary

The purpose of this open-label study is to evaluate the pharmacokinetics, safety, and tolerability of subcutaneously (SC; under the skin) administered GAMUNEX-C compared to intravenously (IV; through the vein) administered GAMUNEX-C in subjects 2-16 years of age with Primary Immunodeficiency.

Read the detailed description

This study was a multi-center, open-label, single-sequence, crossover study to evaluate the pharmacokinetics (PK), safety and tolerability of SC-administered GAMUNEX-C in pediatric PI subjects (ages 2-16). The study consisted of a Screening Phase, Run-in Phase, two treatment phases (an IV Phase and a SC Phase), and an End of Study/Early Termination (EOS/ET) visit. Run-in phase: 3 - 4 months, IV Phase: \~ 4 - 5 weeks, SC Phase: 12 weeks, and End of Study/Early Termination (EOS/ET) visit: one week after SC Week #12.

03

Conditions studied

  • Primary Immunodeficiency
04

Who can participate

Ages eligible
2 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 2-16 years old, inclusive.
  • Documented and confirmed pre-existing diagnosis of PI with features of hypogammaglobulinemia requiring immunoglobulin replacement.
  • Currently on IgG replacement therapy with a serum IgG trough concentration of ≥ 500 mg/dL at the Screening Visit.
  • Adequate normal skin to allow for SC infusions.
  • Signs an assent form, if applicable (per Institutional Review Board [IRB] requirements). Parent or legal guardian must sign an form.
  • Females of must have a negative urine pregnancy test result and must practice an effective form of (which may include abstinence).

Exclusion criteria

Exclusion Criteria:

  • History of anaphylaxis or severe systemic response to an immunoglobulin or blood product.
  • History of blistering skin disease, thrombocytopenia, bleeding disorder, recurrent skin infections or other disorders where subcutaneous therapy could be .
  • Has a specific antibody deficiency disorder, IgG subclass deficiency, or transient hypogammaglobulinemia of infancy.
  • History of severe adverse reaction to parenteral products containing immunoglobulin A (IgA).
  • Significant proteinuria and/or has a history of acute renal failure and/or severe renal impairment (serum creatinine more than 2.5 times the [ULN] for age and gender) and/or is on dialysis.
  • Known substance or prescription drug abuse in the past 12 months.
  • Acquired medical condition that is known to cause secondary immune deficiency.
  • Receiving any of the following medications: systemic (long term daily, >1 mg of prednisone equivalent/kg/day for >30 days) (intermittent courses would not exclude subject); (i.e., antimetabolites and systemic calcineurin inhibitors; NOTE: inhaled steroids are allowed); or immunomodulators.
  • Non-controlled arterial hypertension at a level of ≥ the 90th percentile blood pressure (either systolic or diastolic) for age and height (based on http://www.nhlbi.nih.gov/guidelines/hypertension/child_tbl.pdf ).
  • History or current diagnosis of thrombotic episodes; venous thrombus that occurred in association with a medical device > 2 years prior to screening are allowed.
  • Currently receiving anti-coagulation therapy.
  • History of Kawasaki disease.
  • Participated in another clinical trial involving exposure to an product or device within 30 days prior to screening (imaging studies without investigative treatments are permitted) or has received any investigational blood product within the previous 3 months.
  • Unable or unwilling to comply with any aspect of the protocol, including blood sampling and completion of the Infusion Site Reactions pages in the SC Infusion Diary.
  • In the opinion of the Investigator the subject may have compliance problems with the protocol and the procedures of the protocol.
  • Pregnant or lactating.
  • Clinical evidence of any significant acute or chronic disease that, in the opinion of the Investigator, may interfere with successful completion of the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Active comparator
    Intravenous GAMUNEX-C

    Biological: GAMUNEX-C

  • Experimental
    Subcutaneous GAMUNEX-C

    Biological: GAMUNEX-C

Interventions

  • BiologicalGAMUNEX-C

    GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Intravenous Administration: 200-600 mg/kg per intravenous infusion every 3-4 weeks

  • BiologicalGAMUNEX-C

    GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Subcutaneous Administration: weekly subcutaneous infusion at a mg/kg dose based on subject's intravenous dose and dosing interval x 1.37 conversion factor

06

What researchers measure

Primary outcomes

  1. Steady-state Area Under the Curve (AUC) for Serum Total Immunoglobulin (IgG)

    Steady-state area under the curve (AUC): For the IV phase, the mean adjusted AUC was calculated for all 11 subjects, which included subjects on both 3 and 4 week intravenous (IV) dosing schedules and who had sufficient immunoglobulin G (IgG) data. For the SC phase, the mean AUC was calculated for 10 subjects on weekly subcutaneous (SC) administration and who had sufficient IgG data.

    Time frame: 4 to 5 weeks for IV administration; 12 weeks for SC administration

  2. Mean Trough of Serum Total IgG

    Mean trough serum total IgG values were calculated for each subject for the IV Phase (IV #1 and IV #2) and the SC phase (SC Weeks #9 and #12, and End of Treatment/Early termination visit). Mean trough concentration values of serum total IgG during the IV and SC phases were calculated based on the IgG population (subjects who received any amount of study drug and had serum total IgG concentration data).

    Time frame: 4 - 5 weeks of IV administration and 12 weeks for SC administration

07

Results

Posted Jan 28, 2015

Participant flow

A total of 13 subjects were screened for participation in this study. After screening, one subject discontinued the study and did not receive study drug. Eleven subjects entered the Run-in phase. One subject entered intravenous Gamunex-C phase directly. A total of 11 subjects entered the IV phase and subsequently entered the SC phase.

Run-in Phase
Participant flow — Run-in Phase
MilestoneIntravenous GAMUNEX-CSubcutaneous GAMUNEX-C
Started110
Completed100
Not completed10
Withdrew: Protocol violation10
Intravenous (IV) Phase
Participant flow — Intravenous (IV) Phase
MilestoneIntravenous GAMUNEX-CSubcutaneous GAMUNEX-C
Started110
Completed110
Not completed00
Subcutaneous (SC) Phase
Participant flow — Subcutaneous (SC) Phase
MilestoneIntravenous GAMUNEX-CSubcutaneous GAMUNEX-C
Started011
Completed010
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimarySteady-state Area Under the Curve (AUC) for Serum Total Immunoglobulin (IgG)

Steady-state area under the curve (AUC): For the IV phase, the mean adjusted AUC was calculated for all 11 subjects, which included subjects on both 3 and 4 week intravenous (IV) dosing schedules and who had sufficient immunoglobulin G (IgG) data. For the SC phase, the mean AUC was calculated for 10 subjects on weekly subcutaneous (SC) administration and who had sufficient IgG data.

Time frame:
4 to 5 weeks for IV administration; 12 weeks for SC administration
Reported as:
Mean · h*mg/dL
Steady-state Area Under the Curve (AUC) for Serum Total Immunoglobulin (IgG)
h*mg/dLIntravenous GAMUNEX-CSubcutaneous GAMUNEX-C
Steady-state Area Under the Curve (AUC) for Serum Total Immunoglobulin (IgG)216873.7 (162277.0 to 291785.0)230830.0 (187577.0 to 303913.0)
PrimaryMean Trough of Serum Total IgG

Mean trough serum total IgG values were calculated for each subject for the IV Phase (IV #1 and IV #2) and the SC phase (SC Weeks #9 and #12, and End of Treatment/Early termination visit). Mean trough concentration values of serum total IgG during the IV and SC phases were calculated based on the IgG population (subjects who received any amount of study drug and had serum total IgG concentration data).

Time frame:
4 - 5 weeks of IV administration and 12 weeks for SC administration
Reported as:
Mean · mg/dL
Mean Trough of Serum Total IgG
mg/dLIntravenous GAMUNEX-CSubcutaneous GAMUNEX-C
Mean Trough of Serum Total IgG997.2 (784 to 1320)1325.0 (1077 to 1690)

Adverse events

Collected over Eligible subjects entered into a 3-month Run-in Phase to receive GAMUNEX-C intravenous infusions. Subjects who completed the Run-in Phase then entered the Intravenous (IV) phase (4 - 5 weeks) followed by the subcutaneous (SC) phase (12 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intravenous GAMUNEX-C—0/12 (0%)10/12 (83.3%)
Subcutaneous GAMUNEX-C—1/11 (9.1%)11/11 (100%)
Most frequent serious events
Most frequent serious events
EventIntravenous GAMUNEX-CSubcutaneous GAMUNEX-C
Lower limb fractureInjury, poisoning and procedural complications0/121/11
Most frequent other events
Showing 10 of 50
Most frequent other events
EventIntravenous GAMUNEX-CSubcutaneous GAMUNEX-C
Infusion site erythemaGeneral disorders0/127/11
infusion site painGeneral disorders0/126/11
Infusion site pruritusGeneral disorders0/126/11
Infusion site discomfortGeneral disorders0/123/11
Infusion site haematomaGeneral disorders0/123/11
HeadacheNervous system disorders1/122/11
Infusion site swellingGeneral disorders0/122/11
PyrexiaNervous system disorders1/122/11
Abdominal painGastrointestinal disorders0/122/11
Abdominal pain upperGastrointestinal disorders0/121/11

Baseline characteristics

All 12 enrolled subjects who were infused with any amount of study drug (GAMUNEX-C) were included in the safety population. The demographic data of the safety population are provided.

Age, Categorical
Age, Categorical(Participants)Safety Population
<=18 years12
Between 18 and 65 years0
>=65 years0
Age, Continuous
Age, Continuous(years)Safety Population
Mean10.8 ± 3.7
Sex: Female, Male
Sex: Female, Male(Participants)Safety Population
Female5
Male7
Region of Enrollment
Region of Enrollment(participants)Safety Population
United States12
08

Study locations

4 sites
  • Childrens Hospital Los Angeles
    Los Angeles, California 90027, United States
  • IMMUNOe International Research Centers
    Centennial, Colorado 80112, United States
  • Joe DiMaggio Children's Hospital
    Hollywood, Florida 33021, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Publications

  • Heimall J, Chen J, Church JA, Griffin R, Melamed I, Kleiner GI. Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX(R)-C) in Pediatric Patients with Primary Immunodeficiency Disease. J Clin Immunol. 2016 Aug;36(6):600-9. doi: 10.1007/s10875-016-0311-4. Epub 2016 Jun 25. PubMed 27342758 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2011
First posted
Nov 6, 2011
Start
Nov 2011
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Jan 28, 2015
Last update
Mar 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01465958
Responsible party
Sponsor
First posted
Nov 6, 2011
Start date
Nov 2011
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Jan 28, 2015
Last update
Mar 13, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion